Table 1.
Patient demographics and baseline characteristics.
| Median (IQR) 1 | ||
|---|---|---|
| Sex, n (%) | female | 116 (60.7%) |
| male | 75 (39.3%) | |
| Age (years) 2 | 59.0 (52.0; 65.0) | |
| Disease duration (years) 2 | 12.0 (6.0; 17.0) | |
| HbA1c (%) | 8.3 (7.3, 9.2) | |
| Body weight (Kg) | 95.0 (84.1, 105.2) | |
| BMI (Kg/m2) | 35.6 (31.7; 39.5) | |
| Body fat mass (%) | 41.0 (32.0, 46.0) | |
| Waist diameter (cm) | 113.0 (106.0, 123.0) | |
| Systolic BP (mmHg) | 140.0 (128.0, 156.0) | |
| Diastolic BP (mmHg) | 82.0 (72.0–90.0) | |
| Total cholesterol (mg/dL) | 162.0 (139.0–196.0) | |
| HDL-c (mg/dL) | 42.0 (36.0–50.0) | |
| LDL-c (mg/dL) | 95.0 (76.0–125.0) | |
| TG (mg/dL) | 142.0 (106.3–191.8) | |
1 except when noticed; 2 at the onset of liraglutide therapy. BMI: Body mass index; HbA1c: glycated haemoglobin; BP: blood pressure; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: triglycerides.